BioSpace News Archive

Inspirna, Inc. announced today that data from the ongoing Phase 1b/2 study of ompenaclid (RGX-202) in combination with FOLFIRI and bevacizumab (BEV) in RAS-mutated (RASm) advanced or metastatic colorectal cancer (CRC) will be presented at the European Society for Medical Oncology (ESMO) Congress 2023 being held October 20-24, 2023 in Madrid, Spain.

Mirion Technologies, a leading provider of advanced radiation safety solutions, announced its contribution to the Psyche mission, which launched from the agency’s Kennedy Space Center in Florida on October 13, 2023.

Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2023 financial results on Wednesday, November 8th, before the market opens.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”) today announced positive initial topline data at the 45 mg (safety) dose level from its ongoing Phase 2a clinical trial of its novel and highly selective CDK9 inhibitor, SLS009, in combination with venetoclax and azacitidine (aza/ven) in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) who did not respond or stopped responding to venetoclax-based therapies.

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that multiple abstracts have been accepted for poster presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium, held October 27th and 28th in Boston, MA.

NovApproach Spine, developer of the patented OneLIF™ interbody spinal fusion system which supports a multitude of surgical approaches, announced today the full market launch of the device during the North American Spine Society’s Annual Meeting, Oct. 18 – 21, 2023, in Los Angeles.

Genome Insight is set to unveil clinical research findings on the genetic foundation of rare diseases at the 2023 NORD Rare Disease & Orphan Products Breakthrough Summit (2023 NORD Breakthrough Summit) in Washington, DC.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of five abstracts in amyotrophic lateral sclerosis (ALS) at the XXVI World Congress of Neurology (WCN), being held virtually and in-person in Montreal, Quebec, October 15-19.

YDS Pharmatech, Inc., a pioneering innovator at a transformative juncture in applying AI to drug discovery, announces its participation in this year’s Bio Investor Forum.

As the field of cognitive care expands, the aging global population is bringing heightened attention to neurodegenerative diseases like Alzheimer’s and other forms of dementia.